-
Bayer HealthCare Partners with China Population Welfare Foundation at CIIE for Public Health Initiatives
•
German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the China Population Welfare Foundation (CPWF) at the 7th China International Import Expo (CIIE). The collaboration aims to enhance public health awareness by promoting health science popularization and advocacy activities. Joint Focus on Health Initiatives Under…
-
Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem
•
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a leading German life sciences company, announced last week the opening of a new life sciences incubator in Shanghai, named Bayer Co.Lab Shanghai. The incubator is located in the Shanghai Innovation (SH-INNO) Park within the Zhanghiang biopharma cluster and is part of…
-
Bayer’s Finerenone Shows Promise in Heart Failure Treatment, Outperforms Placebo in Phase III Trial
•
FRANKFURT—Bayer AG (FRA: BAYN) has announced positive results from the Phase III FINEARTS-HF study for its mineralocorticoid receptor (MR) antagonist, finerenone. Originally approved for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes, finerenone is now being developed for heart failure, a condition with significant market potential.…
-
Bayer CEO Joins German Chancellor on China Visit, Announces New Investments
•
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company based in Germany, recently had its CEO, Bill Anderson, accompany German Chancellor Olaf Scholz on a high-profile visit to China. In a brief interview with Xinhua, Anderson emphasized Bayer’s dedication to developing innovative drugs and…
